2017 MPN Challenge

The 2017 MPN Challenge is a grant program from the MPN Research Foundation that aims to change the trajectory and prognosis for patients with myeloproliferative neoplasms.

Myeloproliferative neoplasms (MPNs) are a closely related group of blood cancers that occur when the bone marrow overproduces one of the mature blood elements. While the discovery of JAK2 inhibitors has led to significant improvements in patient care, new approaches are sought in order to better understand and control the progression of MPNs from chronic to life-threatening stages.

This year’s challenge focuses on the elimination of the mutant stem cells which promote the diseases. In addition to the 3 topic areas indicated (eliminating the mutant stem cell directly, eliminating the mutant stem cell indirectly, disrupting the microenvironment), proposals aimed at more clearly understanding the pathogenesis and progression of MPNs will also be reviewed.

Proposals will be accepted starting February 1, 2017 and are due on April 1, 2017. For more information and instructions, see the 2017 MPN Challenge website.

We’ve Added @JoVEJournal Cancer Research!

JoVE Cancer Research illustrates experimental approaches in biomedical research and clinical practice aimed at understanding, detecting, treating and preventing cancer. The articles in the section demonstrate

  • methods to study the cellular and molecular mechanisms of cancer
  • animal models of cancer research
  • development of new therapies and diagnostics
  • tumor imaging
  • chemical and radiation treatments
  • surgical procedures, and
  • improvements in therapy.

JoVE Cancer Research video articles offer researchers and clinical practitioners an efficient way to learn the technologies and experimental methods in cancer research.

Want to publish with JoVE? Go here for information on submissions.

Discover JoVE Cancer Research in our eJournal A-Z listing or TriCat, our library catalog.

The Latest in Cervical Cancer, Breast Cancer and More…

Surfing the web, I uncovered these news items worth sharing

  • A recent article in the New York Times reported on the wide disparity in death rates of cervical cancer between black women and white women. The full study has been published in the journal Cancer.
  • Doctors at the University of Colorado Anschutz Medical Campus have successfully treated a 26 year old female patient diagnosed with brain cancer using the anti-malaria drug, chloroquine. Further discussion can be found in eLife.
  • A new multi-center study found that half of breast cancer patients experience at least one severe side effect from treatment. Side effects led to additional doctor’s appointments, trips to the emergency room, delays in treatment and reduced dosages.  The report was published in Cancer.
  • According to a recent study in PLoS Biology, wearable devices can serve as a health dashboard, monitoring health and sensing early signs of illness, likely even before the person wearing it does.
  • Researchers with The Cancer Genome Atlas (TCGA) Research Network have identified genomic features of cervical cancer that may help with targeted therapies for patients. More information is available on their website.